Market capitalization | $41.93m |
Enterprise Value | $23.56m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1.24 |
P/S ratio (TTM) P/S ratio | 2.21 |
P/B ratio (TTM) P/B ratio | 1.42 |
Revenue growth (TTM) Revenue growth | -14.70% |
Revenue (TTM) Revenue | $18.94m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
4 Analysts have issued a iCAD, Inc. forecast:
4 Analysts have issued a iCAD, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 19 19 |
15%
15%
|
|
Gross Profit | 16 16 |
2%
2%
|
|
EBITDA | -5.59 -5.59 |
40%
40%
|
EBIT (Operating Income) EBIT | -6.12 -6.12 |
41%
41%
|
Net Profit | -3.40 -3.40 |
66%
66%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
iCAD, Inc. is a medical technology company, which engages in the provision cancer detection and therapy solutions. It operates through the Cancer Detection and Cancer Therapy segments. The Cancer Detection segment include image analysis and workflow products. The Cancer Therapy segment consists radiation therapy products. The company was founded in 1984 and is headquartered in Nashua, NH.
Head office | United States |
CEO | Dana Brown |
Employees | 69 |
Founded | 1984 |
Website | www.icadmed.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.